The coming period will not simply be another year of technological progress for healthcare and pharmaceuticals. It will be a year of choices. Choices about which technologies truly mature, which business models prove sustainable, and which organisations manage to turn innovation into real impact for patients and healthcare systems.
With the Horizon Europe 2026–2027 programme fully underway and European policy increasingly focused on resilience, digital transformation and strategic autonomy, developments in digital health and pharmaceuticals are gaining clearer direction.
So what are the key changes expected to shape the future of the sector?
Artificial intelligence moves into clinical practice
Artificial intelligence is gradually moving from experimental pilots into real clinical use — supported by clearer regulatory frameworks.
In the coming years we are likely to see:
-
AI tools supporting diagnosis, prognosis and treatment decisions
-
greater emphasis on reliable and responsible use of AI in healthcare
-
stronger involvement of regulatory authorities from the early stages of AI development
For companies, this marks an important shift. Technology alone is no longer enough. AI solutions must demonstrate clear clinical value, comply with regulatory requirements and make meaningful use of real healthcare data.
Health data: from isolated systems to shared infrastructure
The future of digital health will depend heavily on how healthcare data is managed, shared and protected.
Interoperability between systems, data quality and data security are no longer optional features — they are becoming essential foundations of modern healthcare.
For healthcare and pharmaceutical organisations, one of the key strategic priorities will be the use of real-world data to support:
-
drug research and development
-
personalised medicine
-
health technology assessment and evaluation of medical innovations
The organisations that succeed will be those that learn how to use data responsibly while building trust among patients, healthcare providers and regulators.
Pharma is becoming more digital — and more collaborative
The pharmaceutical ecosystem is also undergoing significant transformation. Digital technologies are reshaping how therapies are developed, tested and delivered.
Digital tools in clinical trials
Digital solutions are changing the way clinical trials are designed and conducted. From remote patient monitoring and real-time data collection to improved patient engagement and compliance, digital tools are helping make studies faster, more efficient and less costly.
Decentralised and hybrid clinical studies
Clinical trials are gradually moving beyond the traditional hospital-centred model. Decentralised and hybrid studies allow patients to participate from different geographic locations, reducing barriers to participation while maintaining data quality and safety.
AI in drug discovery and repurposing
Artificial intelligence is increasingly used to accelerate the discovery of new treatments and identify new therapeutic uses for existing medicines. By analysing large volumes of data, AI can help reduce the time and risk associated with pharmaceutical research and development.
At the same time, it is becoming increasingly clear that progress in healthcare innovation will depend on collaboration — bringing together digital health companies, biotech firms, healthcare providers, startups and research organisations. Innovation ecosystems are therefore gaining growing importance.
Prevention and mental health move to the forefront
Across Europe, prevention is becoming a central priority for healthcare policy.
Particular attention is being given to areas such as non-communicable diseases, mental health among children and young people, and the health impacts of digital lifestyles.
Solutions that combine technology, behavioural science and public health approaches are expected to play an increasingly important role in the coming years.
Less bureaucracy, more strategy
Changes in European funding programmes are also reshaping the innovation landscape.
The trend is moving toward fewer but larger projects, with clearer objectives and measurable outcomes. This approach favours organisations that demonstrate strategic maturity, understand the European policy landscape and can position themselves effectively within international consortia.
The role of Health Hub
In this rapidly evolving environment, Health Hub continues to support organisations and businesses in Greece in positioning themselves within the European digital health and pharmaceutical landscape.
Through its free digital transformation services, strategic guidance, networking opportunities and testing facilities — including “test before invest” services — the Hub acts as a bridge between technology, healthcare policy and real market needs.
Because in the coming years, innovation will not be judged by how advanced it appears, but by how practical, applicable and valuable it becomes in real healthcare settings.